American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Hepion Pharmaceuticals, Inc. (HEPA)

$0.14 +3.70% OTC: HEPA · 15-min delayed

RED BANK, New Jersey
Public · OTC: HEPA

Visit website Follow

$0Revenue · FY2023

-$8.3MNet income

HEPAOTC

About Hepion Pharmaceuticals, Inc.

HEPION PHARMS INC

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Company facts

Type: Public · OTC: HEPA
Headquarters: RED BANK, New Jersey
Industry: Pharmaceuticals
Website: Visit site

Registry IDs

Ticker: HEPA OTC
SEC CIK: 1583771
EIN: 462783806
SIC: 2834 Pharmaceutical Preparations

Explore our data studies: the biggest company in every US state · all rankings & reports.

Embed this company’s badge

Show Hepion Pharmaceuticals, Inc.’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/hepion-pharmaceuticals-inc/"><img src="https://americancompanies.com/badge/hepion-pharmaceuticals-inc.svg" alt="Hepion Pharmaceuticals, Inc. — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it free, control the page, and activate the embeddable Verified badge for their own website.

Claim this profile — free

Track American companies

Create a free account to follow Hepion Pharmaceuticals, Inc. and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2023: $0
Net income: -$8.3M
Total assets: $3.1M

Source: SEC EDGAR · updated Jun 8, 2026

OTC: HEPA

$0.14 +3.70%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$0.03 $0.14

52-week range

Open: —
Day range: –
Prev close: —
Volume: —

Hepion Pharmaceuticals, Inc. (HEPA) Stock Price

Reported a net loss of $8.3M in FY2023.
Trading near its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Hepion Pharmaceuticals, Inc..

Write a review

Newsroom

News about Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd. GlobeNewswire Inc. · 2024-12-11 · neutral Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B GlobeNewswire Inc. · 2024-12-02 · neutral Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial GlobeNewswire Inc. · 2024-04-19 Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell GlobeNewswire Inc. · 2024-03-06 Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds GlobeNewswire Inc. · 2024-02-16 Hepion Pharmaceuticals to Present at NASH-TAG 2024 GlobeNewswire Inc. · 2024-01-03

News & sentiment via Polygon.io

FAQ

Hepion Pharmaceuticals, Inc.: frequently asked questions

Is Hepion Pharmaceuticals, Inc. an American company?

Hepion Pharmaceuticals, Inc. is a US-based company headquartered in Red Bank, New Jersey, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Hepion Pharmaceuticals, Inc. headquartered?

Hepion Pharmaceuticals, Inc. is headquartered in Red Bank, New Jersey, United States.

Is Hepion Pharmaceuticals, Inc. publicly traded?

Yes — Hepion Pharmaceuticals, Inc. is a publicly traded company. Its stock trades under the ticker symbol HEPA on the OTC.

What does Hepion Pharmaceuticals, Inc. do?

Hepion Pharmaceuticals, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore